The Journal is included in Russian and International Library and Abstract Databases
Russain Science Index (Russia)
EBSCO
DOI Registration Agency (USA)

CURRENT POSSIBILITIES OF IMMUNOTHERAPY FOR BREAST CANCER

Download full text PDF
Issue: 
7
Year: 
2015

K. Titov (1,2), Candidate of Medical Sciences; F. Shamilov (1), Candidate of Medical Sciences; D. Ryabchikov (1), Candidate of Medical Sciences; A. Egorova (2), Candidate of Medical Sciences; Professor M. Kiselevsky (1), MD; Professor N. Tupitsin (1), MD; Professor V. Selchuk (1), MD 1 -N.N. Blokhin Russian Cancer Research Center, Moscow 2 -N.I. Pirogov Russian National Research University, Moscow

The clinical efficacy and tolerability of anti-tumor immunotherapy using Russian immunomodulators (Polyoxidonium and Roncoleukin) and autologous lymphokine-activated killer cells were evaluated in patients with breast cancer.

Keywords: 
breast cancer
immunotherapy
interleukin-2
Polyoxidonium
lymphokine-activated killer cells



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Artamonova E.V. Rol' immunofenotipirovanija opuholevyh kletok v diagnostike i prognoze raka molochnoj zhelezy // Immunologija gemopoeza. 2009; 6 (1): 8–51.
  2. Artamonova E.V., Ognerubov N.A., Tupitsyn N.N. i dr. Rak molochnoj zhelezy: immunologicheskie faktory prognoza / Izd-vo Voronezhskogo gosudarstvennogo universiteta, 2005; 240 s.
  3. Bychkov M.B., Titov K.S., Gorbunova V.A. i dr. Sovremennye podhody k lecheniju bol'nyh s opuholevym plevritom, rezistentnym k sistemnoj terapii // Ros. onkol. zhurn. – 2013; 3: 4–8.
  4. Sel'chuk V.Ju., Bychkov M.B., Kiselevskij M.V. (pod red.). Opuholevye serozity: plevrity, astsity, perikardity / M.: Prakticheskaja meditsina, 2011; s. 277.
  5. Semiglazov V.F., Manihas A.G., Semiglazova T.Ju. i dr. Neoad'juvantnaja sistemnaja terapija raka molochnoj zhelezy / SPb: Agraf, 2012; 110 s.
  6. Subbotina A.A., Letjagin V.P., Tupitsyn N.N. i dr. Rol' immunofenotipirovanija raka molochnoj zhelezy v protsesse neoad'juvantnoj himioterapii // Immunologija gemopoeza. – 2009; 6 (1): 52–78.
  7. Titov K.S., Demidov L.V., Shubina I.Zh. i dr. Tehnologii kletochnoj immunoterapii v lechenii bol'nyh so zlokachestvennymi novoobrazovanijami // Vestnik RNIMU im. N.I. Pirogova. – 2014; 1: 42–7.
  8. Titov K.S., Sel'chuk V.Ju., Gritsaj A.N. i dr. Vnutripolostnaja bioterapija metastaticheskih serozitov u bol'nyh s opuholjami zhenskoj reproduktivnoj sistemy // Palliativnaja meditsina i reabilitatsija. – 2010; 3: 44–50.
  9. DeNardo D., Drennan D., Rexhepaj E. et al. Leucocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy // Cancer Discovery. – 2011; 1 (1): 54–67.
  10. Liu X., Li D., Zhang C. et al. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogenic LAK cells combined with rIL-2 // Med. Sci. J. – 1993; 8: 186–9.
  11. Ohara M., Okada M. Dose-finding study of anti-CD25 antibody for targeting regulatory T cells in locoregional immunotherapy of malignant effusion // Hiroshima J. Med. Sci. – 2008; 57: 37–46.
  12. Ruffel B., Au A., Rugo H. et al. Leucocyte composition in human breast cancer // PNAS. – 2012; 109 (8): 2796–801.
  13. Shubina I., Volkov S., Titov K. et al. Intraplevral IL-2/LAK Therapy of NSCLC Patients with Malignant Effusion. The 2nd Russia–Japanese International Conference on Lang Cancer. Tokyo, Japan, 2006; Abstracts Book: p. 14.